-
Light-chain-restricted Russell body oral mucositis: an immunohistochemical study and literature review Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-18 Luana Stefanie Silvino Gonçalves, Karina Helen Martins, Magdalena Raquel Torres Reyes, Isabella Silva Catananti, Fernando Chahud, Jorge Esquiche León
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Management of relapsed/refractory mantle cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-18 Musa Alzahrani, Diego Villa
In this review we summarize the current evidence describing the management of patients with relapsed/refractory MCL and outline the various novel therapeutics that have been developed over the past...
-
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-18 Jose Tinajero, Dat Ngo, Jianying Zhang, Ni-Chun Tsai, Ahmed Aribi, Ibrahim Aldoss, Vaibhav Agrawal, Shukaib Arslan, Idoroenyi Amanam, Hoda Pourhassan, Karamjeet Sandhu, Monzr Al-Malki, Vinod Pullarkat, Pamela Becker, Ryotaro Nakamura, Anthony Stein, Guido Marcucci, Andrew Artz, Paul Koller, Amandeep Salhotra
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-17 Ibrahim Aldoss, Jianying Zhang, Marjorie Robbins, Joo Song, Monzr M. Al Malki, Salman Otoukesh, Karamjeet Sandhu, Vaibhav Agrawal, Alex F. Herrera, Leslie L. Popplewell, Lucy Ghoda, Anthony Stein, Guido Marcucci, Stephen Forman, Vinod Pullarkat
CD123 “expression” is common in hematological malignancies, including acute lymphoblastic leukemia (ALL). Flotetuzumab is a novel, investigational CD3/CD123 DART®. We conducted a phase 1 study eval...
-
COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-16 Naokazu Nakamura, Hiroko Tsunemine, Ryo Ikunari, Tomomi Sakai, Nobuyoshi Arima
Knowledge of the SARS-CoV-2 antibody titers induced by tixagevimab–cilgavimab in patients with hematologic diseases remains insufficient. Here, we performed a single-center, prospective study to re...
-
Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL) Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-16 Imran Haider, Darryl P. Leong, Martha Louzada, Arleigh McCurdy, Gregory R. Pond, Ruthanne Cameron, Mohammed Aljama, Alissa Visram, Tanya M. Wildes, Hira Mian
There is limited knowledge regarding the prevalence of geriatric impairments and frailty among patients with multiple myeloma (MM) in a real-world setting. This study evaluated the distribution of ...
-
B cell receptor signaling proteins as biomarkers for progression of CLL requiring first-line therapy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-15 Mischa Y. L. Vervoordeldonk, Paul J. Hengeveld, Mark-David Levin, Anton W. Langerak
The molecular landscape of chronic lymphocytic leukemia (CLL) has been extensively characterized, and various potent prognostic biomarkers were discovered. The genetic composition of the B-cell rec...
-
The impact of race and ethnicity on diffuse large B-cell lymphoma outcomes within the veterans health administration (VHA) Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-15 Andrew Ta, Supreet Kaur, Michael Mader, Kathleen Franklin, Madison Williams, Ryan Williams, Jean-Pierre Blaize, Amna Naqvi, Snegha Ananth, Michael Song, Brian Oliver Warnecke, Abhishek Pandya, Lakene Raissa Djoufack Djoumessi, Phillip Nazarewicz, Manuel Espinoza-Gutarra, Kana Tai Lucero, Jennifer Whitehead, Alaq Al-Abayechi, Lauren Boyle, Sophia Lee, Gabriel Roman Souza, Esteban Toro Velez, Ian Mines
We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 patients who met inclusion criteria were p...
-
Two recurrent types of IGH::5′ BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-12 Fumiyo Maekawa, Masahiko Hayashida, Kayo Takeoka, Katsuhiro Fukutsuka, Miho Nakagawa, Takashi Akasaka, Shinichi Sakamoto, Shinji Sumiyoshi, Yoichiro Kobashi, Hitoshi Ohno
We describe two types of IGH::BCL2 breakpoints involving the 5′ region of BCL2 (5′ BCL2). One was ins(14;18)(q32;q21q21) observed in 2 follicular lymphoma (FL) cases, in which IGH was cleaved at 3’...
-
Successful treatment with cladribine in a patient with Rosai–Dorfman disease complicated by severe, prolonged marrow aplasia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-12 Tadeusz Robak, Marcin Braun, Anna Guminska, Elżbieta Iskierka-Jażdżewska, Paweł Robak
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Correction Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-12
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-11 Giovanni Palladini, Michaela Liedtke, Wagner Zago, Phil Dolan, Gene G. Kinney, Morie A. Gertz
Amyloid light chain (AL) amyloidosis is a progressive plasma cell disorder caused by amyloid deposition resulting in organ damage and failure. Current standard-of-care treatments target clonal plas...
-
Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112) Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-10 Juan-Manuel Sancho, Pau Abrisqueta, Abhijeet Kumar, Raul Cordoba, Monica Tani, Peter Langmuir, Erica Rappold, Teng Liu, Armando Lopez-Guillermo
Parsaclisib, a potent and highly selective phosphoinositide 3-kinase δ inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. The phase 1 CITADEL-112 (NCT03424122) stu...
-
Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-10 Lauren Schaff, Lakshmi Nayak, Christian Grommes
The incidence of primary central nervous system lymphoma (PCNSL) has steadily increased, particularly in elderly patients. Although highly responsive to first-line chemotherapy and radiotherapy, ap...
-
The prognostic significance of genomic complexity in patients with CLL Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-09 Ellinor Goergen, Othman Al-Sawaf
Chromosomal aberrations are a common feature of cancer and can fuel cancer progression and treatment resistance. In chronic lymphocytic leukemia (CLL), the presence of multiple chromosomal aberrati...
-
Normal and malignant cells are homogeneously distributed in the bone marrow of children Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-08 Sharon Veenbergen, Romana Jugooa, Jeroen te Marvelde, Andrica C.H de Vries, Vincent H. J. van der Velden
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Gammopathic dermopathy: characterization of cutaneous MGUS Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-06 Emily R. Gordon, Caroline Chen, Megan H. Trager, Oluwaseyi Adeuyan, Brigit A. Lapolla, Lauren M. Fahmy, Celine M. Schreidah, David A. Wetter, Larisa J. Geskin
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a clonal plasma cell disorder that is considered preneoplastic, asymptomatic, and only requiring observation. However, MGUS may result i...
-
Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell lymphoma in the United States Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-03 Chendi Cui, Chaoling Feng, Ning Rosenthal, Sally W. Wade, Laura Curry, Christine Fu, Gunjan L. Shah
The efficacy of chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is well-established. This study, using the Premier PINC AI Healthcare Database, assessed hospital cos...
-
Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-01 Yuqin Song, Jianyong Li, Keshu Zhou, Xiaoyan Ke, Zhen Cai, Huilai Zhang, Tingting Yao, Zhen Xia, Yiqiu Wang, Peiqiong Lai, Xiaofeng Liu, Jun Zhu
Acalabrutinib studies have limited Asian participation. This phase 1/2 study (NCT03932331) assessed acalabrutinib in Chinese patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). Prim...
-
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant Leuk. Lymphoma (IF 2.6) Pub Date : 2024-04-01 Yaqing Cao, Jingjing Shang, Yingying Zhai, Qingyuan Wang, Lingzhi Yan, Xiaolan Shi, Jing Wang, Ying Yao, Huifen Zhou, Aining Sun, Miao Miao, Chengcheng Fu, Song Jin
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-27 Andrew Matthews, Elena Fenu, Sarah J. Skuli, Jaryse C. Harris, Catherine Lai
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML) Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-27 Jorge Cortes, Brian A. Jonas, Gary Schiller, Alice Mims, Gail J. Roboz, Andrew H. Wei, Pau Montesinos, P. Brent Ferrell, Karen WL. Yee, Pierre Fenaux, Anthony Schwarer, Justin M. Watts
Olutasidenib, a potent, selective, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, is FDA-approved for relapsed/refractory (R/R) acute myeloid leukemia (AML). Here we report efficacy and...
-
Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-22 Maria-Myrsini Tzioni, Alexandra Clipson, Zi Chen, Francesco Cucco, Andrew Wotherspoon, Stefan Dojcinov, Ming-Qing Du
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Significant impact of antibiotic exposure on GI-GVHD, NRM, and GRFS following allogeneic HCT with non-myeloablative Flu-TBI conditioning Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-23 Lenneke F. J. van Groningen, Suzanne van Dorp, Manita E. J. Bremmers, Shahira Fazel, Mieke W. H. Roeven, Nicole M. A. Blijlevens, Walter J. F. M. van der Velden
Acute gastro-intestinal graft-versus-host disease (GI-GVHD) and non-relapse mortality (NRM) after allogeneic HCT are closely related to loss of microbial diversity and intestinal dominance by singl...
-
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-22 Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K. Barta, Seda Tolu, Brian Estrella, Ahmed Sawas, Jennifer K. Lue, Mark M. Francescone, Barbara Pro, Jennifer E. Amengual
Previously, we conducted a Phase I study of the combination of pralatrexate and romidepsin in patients with relapsed/refractory (R/R) lymphomas and subsequently conducted a multicenter Phase II stu...
-
Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-21 Aya M. Abdallah, Hanafy Hafez, Youssef Madney, Sonia Ahmed, Dina Yassin, Sherine Salem, Rodina Yousry, Hisham Abdel-Azim, Leslie Lehmann, Alaa Elhaddad
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Treatment outcome, toxicity, and quality of life of patients with bronchus-associated lymphoid tissue lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-20 Lin-Rui Gao, Xinyue Wang, Yunpeng Wu, Xiao-Li Feng, Wei Rao, Xin Liu, Yong-Wen Song, Hui Fang, Bo Chen, Jing Jin, Yue-Ping Liu, Hao Jing, Yuan Tang, Ning-Ning Lu, Ning Li, Wen-Wen Zhang, Yirui Zhai, Shu-Lian Wang, Shu-Nan Qi, Ye-Xiong Li
The disease failure patterns and optimal treatment of bronchus-associated lymphoid tissue (BALT) lymphoma are unknown. This retrospective study involved 71 patients with primary BALT lymphoma who h...
-
RAD21 mutations in acute myeloid leukemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-20 Dorottya Laczko, Corey Poveda-Rogers, Andrew H. Matthews, Oraine Snaith, Selina Luger, Adam Bagg, Gabriel C. Caponetti, Jennifer J.D Morrissette, Guang Yang
The cohesin complex is a ring-shaped protein structure involved in DNA repair and chromosomal segregation. Studies have showed that genomic alterations in the cohesin complex members are among the ...
-
Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-19 Gilad Itchaki, Osnat Jarhovsky, Jorge J. Castillo, Hamza Hassan, Moshe L. Gatt, Merav Leiba, Pia Raanani, Morie A. Gertz, Iuliana Vaxman
The simultaneous occurrence of Waldenström macroglobulinemia and multiple myeloma in the same patient has been published as case reports. Patients with Waldenström macroglobulinemia often have a sm...
-
Corynebacterium bacteremia in patients with hematologic disorders: a case series and systematic literature review Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Tomohito Shimada, Kazuhiro Ishikawa, Fujimi Kawai, Nobuyoshi Mori
Corynebacterium is generally considered a contaminant in clinical practice. However, it may cause bacteremia in patients with hematologic disorders, and factors that contribute to its mortality are...
-
Inhibitory effect of a neddylation blockade on HTLV-1-infected T cells via modulation of NF-κB, AP-1, and Akt signaling Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-15 Chie Ishikawa, Naoki Mori
Adult T-cell leukemia (ATL), caused by HTLV-1, is the most lethal hematological malignancy. NEDD8-activating enzyme (NAE) is a component of the NEDD8 conjunction pathway that regulates cullin-RING ...
-
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-19 Vikas Gupta, Stephen Oh, Timothy Devos, Viviane Dubruille, John Catalano, Tim C. P. Somervaille, Uwe Platzbecker, Pilar Giraldo, Hiroshi Kosugi, Tomasz Sacha, Jiri Mayer, Arpad Illes, Catherine Ellis, Zhaohui Wang, Francisco J. Gonzalez Carreras, Bryan Strouse, Ruben Mesa
A key hallmark of myelofibrosis is anemia, which ranges from mild to severe based on hemoglobin levels. To more clearly define outcomes with the Janus kinase (JAK) 1/JAK2/activin A receptor type 1 ...
-
Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Li Li, Wenjing Yang, Yuanyuan Pan, Ruyu Ye, Yu Wang, Sijia Li, Haoyan Jiang, Qi Zhang, Xiaobo Wang, Jinsong Yan
Chidamide (CS055/HBI-8000, tucidinostat) has shown promising effects in the clinical treatment of various hematologic tumors. Diffuse large B-cell lymphoma (DLBCL) has shown highly heterogeneous bi...
-
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Oriol, Philippe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios Athanasios Dimopoulos
Once-weekly carfilzomib at 56 mg/m2 plus immunomodulatory drugs and dexamethasone has shown efficacy and tolerability treating early relapsed/refractory multiple myeloma (RRMM). The phase 2 SELECT ...
-
Pairing obinutuzumab with venetoclax in relapsed CLL Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Kerry A. Rogers, Philip A. Thompson
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-14 Thulasi Raman Ramalingam
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-12 Jinjin Zhu, Mimi Xu, Yuhua Ru, Huanle Gong, Yiyang Ding, Ziling Zhu, Yang Xu, Yi Fan, Xiang Zhang, Yuqing Tu, Aining Sun, Huiying Qiu, Zhengming Jin, Xiaowen Tang, Yue Han, Chengcheng Fu, Suning Chen, Xiao Ma, Feng Chen, Tiemei Song, Depei Wu, Jia Chen
Cytomegalovirus (CMV) reactivation increases treatment-related mortality (TRM) after allogeneic hematopoietic cell transplantation (allo-HCT). We analyzed 141 adult acute leukemia (AL) patients suf...
-
The value of bispecific antibodies in relapsed and refractory DLBCL Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-07 Katharine Louise Lewis, Chan Yoon Cheah
Diffuse large B-cell lymphoma (DLBCL) may be cured with anti-CD20 based chemoimmunotherapy in the majority of cases, however, relapsed/refractory disease occurs in 30–40% patients, and despite sign...
-
Correction Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-09
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-09 Max J. Gordon, Sigrid Dubois, Bonita Bryant, Samuel Ng, Kevin Conlon, Milos D. Miljkovic, Thomas Waldmann, Mark Roschewski
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-08 Brian T. Hill, Yanwen Chen, Deepa Jagadeesh, Robert Dean, Omer Koc, Kirsten Boughan, Brenda Cooper, Brad Pohlman, Paolo Caimi, Mitchell R. Smith
Lenalidomide and rituximab (R2) is an effective frontline treatment for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). We investigated the safety and efficacy of addition of the proteas...
-
A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-05 Marie Leroy, Laure Deramoudt, Marine Pinturaud, Julie Demaret, Enagnon Kazali Alidjinou, Morgane Nudel, Doriane Cavalieri, Wadih Abou Chahla, Pascal Odou, Franck Morschhauser, Ibrahim Yakoub-Agha, Nicolas Simon, David Beauvais
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-07 Wisdom Akingbemi, Goldie Kurtz, Nikhil Yegya-Raman, John P. Plastaras, Stephen J. Schuster, Elise A. Chong
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-03 Jacob Fang, Grace Bosma, Dara Aisner, Christine McMahon, Maria Amaya, Marc Schwartz, Jeff Kaiser, Diana Abbott, Zenggang Pan, Jeffrey Schowinsky, Changlee Pang, Jonathan A. Gutman, Daniel A. Pollyea
Predictors for response to intensive therapy in AML have focused on baseline factors: percent leukemic blasts in marrow, cytogenetic/molecular genetic abnormalities, and presence of secondary AML. ...
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-05 Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, Caner Saygin, Mariam T. Nawas, Michael W. Drazer, Adam S. DuVall, Satyajit Kosuri, Michael J. Thirman, Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Anand A. Patel
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-03 C. Quivoron, J.-M. Michot, A. Danu, H. Lecourt, V. Saada, K. Saleh, V. Vergé, S. Cotteret, O. A. Bernard, V. Ribrag
As a promising alternative to bone marrow aspiration (BMA), mutational profiling on blood-derived circulating cell-free tumor DNA (cfDNA) is a harmless and simple technique to monitor molecular res...
-
A rare case of TEMPI syndrome (telangiectasias, erythrocytosis, monoclonal gammopathy and ascites) associated with IgM monoclonal gammopathy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-28 Stavroula Asimakopoulou, Panagiotis Malandrakis, Aikaterini Kamiliou, Maria Gavriatopoulou, Konstantina Bafa, Vaios Samaras, Amalia Anastasopoulou, Eleni Variami, Eleftheria Lakiotaki, Penelope Korkolopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Evangelos Cholongitas
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-29 Adrian Minson, Michael Dickinson
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the eyes – an unusual clinicopathologic presentation with hyperdiploid clone Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-26 Sudipta Naskar, Tanusree Paul, Jayashree D. Kulkarni, K. C. Anand, V. Divya, Harshitha D. Rambhojun
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Potential genetic mechanisms driving B/myeloid conversion in patients with follicular lymphoma and Langerhans cell neoplasms Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-21 Mehrnoosh Tashakori, L. Jeffrey Medeiros
Transformation of follicular lymphoma (FL) to a Langerhans cell (LC) neoplasm is extremely uncommon. The shared IGH::BCL2 rearrangement is a robust finding in most transformed tumors underscoring t...
-
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-21 Ronald Nemec, Marielle Scherrer-Crosbie, Jeremy S. Abramson, Robert Redd, Hannah K. Gilman, Terry Ho, Jessica Wu, Julius Heemelaar, Donna Neuberg, Ephraim P. Hochberg, Jeffrey A. Barnes, Philippe Armand, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Robb S. Friedman, Ann S. LaCasce, Tomas G. Neilan, Jacob D. Soumerai
STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We p...
-
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-23 Naveen Pemmaraju, Yazan F. Madanat, David Rizzieri, Salman Fazal, Raajit Rampal, Gabriel Mannis, Eunice S. Wang, James Foran, Andrew A. Lane
BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic cells and is characterized by CD123 overexpression, which is seen in all pa...
-
Immunochemotherapy triggered reversible cerebral vasoconstriction syndrome in a patient with intravascular large B-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-22 Chong Wei, Feifei Zhai, Congwei Jia, Wei Zhang, Daobin Zhou, Yan Zhang
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-22 Kevin D. Hofer, Marco M. Bühler, Marco Roncador, Markus Rechsteiner, Ewerton M. Maggio, Joëlle Tchinda, Urs Schanz, Eugenia Haralambieva, Corinne C. Widmer
There is increasing evidence that therapy-related acute lymphoblastic leukemia (trALL) resulting from chemo- and/or radiotherapy represents a distinct entity. However, apart from KMT2A rearrangemen...
-
Parameters of body composition do not predict survival in patients with multiple myeloma undergoing autologous stem cell transplantation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-21 Felix Barajas Ordonez, Denise Wolleschak, Yannic Zeller, Mattes Hinnerichs, Pablo Rodríguez-Feria, Anar Aghayev, Martin Mikusko, Jan Borggrefe, Dimitrios Mougiakakos, Alexey Surov
Studies regarding the influence of body composition parameters as predictors on overall survival (OS) in patients with multiple myeloma (MM) are scarce. OS and progression-free survival (PFS) were ...
-
A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-19 Lindsey Murphy, Bradford Siegele, Billie Carstens, Lisa Hartman, Kelly Faulk
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021 Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-13 Anju Murayama, Hinari Kugo, Sae Kamamoto
Financial interactions between healthcare industry and pediatric hematologist/oncologists (PHOs) could be conflicts of interest. Nevertheless, little is known about financial relationships between ...
-
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-12 Isha Mol, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek
For patients with triple-class exposed/refractory multiple myeloma (TCE/RMM), where effective treatments options are limited, B-cell maturation antigen and CD3-directed bispecific antibodies offer ...
-
Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-10 Simon Østergaard, Lone Schejbel, Marie Fredslund Breinholt, Mette Ølgod Pedersen, Troels Hammer, Lars Munksgaard, Peter Nørgaard, Estrid Høgdall, Lise Mette Rahbek Gjerdrum, Torsten Holm Nielsen
Next-generation sequencing (NGS) affords comprehensive insights into the genomic landscape of lymphomas. We examined the mutational pattern in patients with Waldenström macroglobulinemia (WM) or ly...
-
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-12 Katja Weisel, Meletios A. Dimopoulos, Meral Beksac, Xavier Leleu, Joshua Richter, Bart Heeg, Sachin Patel, Istvan Majer, Ian McFadden, Joseph Mikhael
Nearly all patients with multiple myeloma eventually relapse or become refractory to treatment. Lenalidomide is increasingly administered in the frontline until disease progression or intolerance t...